The effect of unsuppressed HIV on T-cell response to COVID-19

NewsGuard 100/100 Score

Scientists have developed several pharmaceutical and non-pharmaceutical interventions to contain the current coronavirus disease 2019 (COVID-19) pandemic, which is caused by the rapid outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For example, the rapid development of COVID-19 vaccines has been instrumental in the prevention of severe illness and deaths worldwide.

In Africa, owing to poor vaccination coverage, the intensity of severe infection and death due to SARS-CoV-2 infection remains high. Additionally, the emergence of new SARS-CoV-2 variants has reduced the efficacy of available vaccines and therapeutics, which are based on the spike protein of the original virus. The World Health Organization (WHO) has classified these SARS-CoV-2 variants as variants of concern (VOC) and variants of interest (VOI). 

Study: Unsuppressed HIV infection impairs T cell responses to SARS-CoV-2 infection and abrogates T cell cross-recognition. Image Credit: Vecctor-3D / Shutterstock.com

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

HIV and COVID-19

The effect of COVID-19 in patients with human immunodeficiency virus (HIV) is not clear. In one study based on small sample size, researchers report that people living with HIV (PLWH) exhibited similar COVID-19 outcomes compared to healthy individuals.

However, a larger epidemiological study has contradicted the previous report and identified increased hospitalization and death rates due to COVID-19 among PLWH as compared to HIV-negative individuals.

One previous study revealed that prolonged shedding of high titers SARS-CoV-2 and the emergence of many mutations were found in individuals with advanced HIV and antiretroviral treatment (ART) failure. Scientists have stated that both B-cells and T-cells play important roles in providing protection against SARS-CoV-2 infection.

Interestingly, studies have shown that T-cell responses can offer protection even in the absence of humoral responses. This implies that in an individual with inherited B-cell deficiencies or hematological malignancies, T-cells will play an important role in their recovery from SARS-Cov-2 infection.

Previous reports have indicated that COVID-19 severity is related to a weak SARS-CoV-2-specific CD4⁺ T-cell polyfunctionality potential. Several studies have also shown that messenger ribonucleic acid (mRNA) vaccines can stimulate Th1 and Th2 CD4+ T-cell responses, which can be correlated with post-boost CD8+ T-cell responses and neutralizing antibodies. Thus, scientists have expressed the need for more insights regarding T-cell-mediated protection against SARS-CoV-2 infection.

About the study

In sub-Saharan Africa, the prevalence of HIV is high; thus, it is important to determine the effect of HIV in individuals diagnosed with COVID-19. Understanding the disease outcome in this patient population will help researchers and policymakers formulate effective strategies to protect them from SARS-CoV-2 infection.

A new study posted to the medRxiv* preprint server evaluates the impact of HIV infection on the quality and epitope specificity of SARS-CoV-2 T-cell responses during the first and second waves of COVID-19 in South Africa. In this study, scientists investigated the antigen-specific CD4+ and CD8+ T-cell responses in a cohort of SARS-CoV-2- infected individuals with and without HIV infection.

Herein, flow cytometry was used to estimate T-cell responses following peripheral blood mononuclear cell (PBMC) stimulation with SARS-CoV-2 peptide pools. The researchers also measured T-cell immunodominance hierarchies and determined the possibility of SARS-CoV-2 escape from T cell recognition through culture expansion.

Study findings

The first COVID-19 wave in South Africa was dominated by the wildtype D614G strain of SARS-CoV-2, whereas the second wave was dominated by the Beta variant. PBMCs were utilized to evaluate the effect of HIV infection on SARS-CoV-2 specific T-cell responses and determine T-cell cross-recognition.

Comparison of SARS-CoV-2 protein targeting by T cell responses among HIV negatives, suppressed and viremic donors:

Comparison of SARS-CoV-2 protein targeting by T cell responses among HIV negatives, suppressed and viremic donors: The magnitude of (a) CD4+ T and (b) CD8+ T cell responses targeting SARS-CoV-2 proteins among study groups. P-values for differences among the groups are *<0.05; as determined by the Mann-Whitney U test. (GraphPad Prism version 9.3.0)

Impaired SARS-CoV-2 specific T-cell responses were identified in individuals with unsuppressed HIV infection. The researchers observed a low count of CD4+ T-cells, with hyperimmune activation, found to be related to reduced SARS-CoV-2 specific T-cell responses.

The scientists also determined spike mutations in the Beta variant, which caused abrogate recognition by memory T-cells raised against epitopes of the original SARS-CoV-2 strain. Likewise, immune responses against SARS-CoV-2 Beta variant epitopes poorly cross recognized corresponding original SARS-CoV-2 strain epitopes, thus demonstrating the ability of certain SARS-CoV-2 variants to escape T-cell recognition.

Individuals with unsuppressed HIV infection were found to exhibit poor responses to SARS-CoV-2 infection. Furthermore, HIV-induced immune defects such as low CD4+ T-cell counts, higher HIV plasma viral loads, and increased immune activation conferred reduced SARS-CoV-2 responses.

HIV-seronegative individuals exhibited robust CD4+ and CD8+ T-cell responses against the SARS-CoV-2 spike protein compared to the PLWH. Furthermore, reduced T-cell cross-recognition was observed between the two COVID-19 waves, which was more prominent in people with unsuppressed HIV infection.The impact of HIV markers of diseases progression on SARS-CoV-2 T cell immunity. (a) CD4+ T cell activation graphed based on the frequency of CD38/HLA-DR co-expressing cells. (b) Correlation between CD4+ T cell activation and absolute CD4 counts. (c) Correlation between CD4+ T cell activation and HIV plasma viral load. (d) CD8+ T cell activation measured by CD38/HLA-DR. (e) Correlation between CD8+ T cell activation and absolute CD4 counts. (f) Correlation between CD8+ T cell activation and HIV plasma viral load.

The impact of HIV markers of diseases progression on SARS-CoV-2 T cell immunity. (a) CD4+ T cell activation graphed based on the frequency of CD38/HLA-DR co-expressing cells. (b) Correlation between CD4+ T cell activation and absolute CD4 counts. (c) Correlation between CD4+ T cell activation and HIV plasma viral load. (d) CD8+ T cell activation measured by CD38/HLA-DR. (e) Correlation between CD8+ T cell activation and absolute CD4 counts. (f) Correlation between CD8+ T cell activation and HIV plasma viral load.

Conclusions

Unsuppressed HIV infection significantly impairs T-cell responses to SARS-CoV-2 infection and reduces T-cell cross-recognition. These findings explain the increased vulnerability of PLWH to severe COVID-19, as well as highlight their susceptibility to infection with emerging SARS-CoV-2 variants.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 12 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Dr. Priyom Bose

Written by

Dr. Priyom Bose

Priyom holds a Ph.D. in Plant Biology and Biotechnology from the University of Madras, India. She is an active researcher and an experienced science writer. Priyom has also co-authored several original research articles that have been published in reputed peer-reviewed journals. She is also an avid reader and an amateur photographer.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bose, Priyom. (2023, May 12). The effect of unsuppressed HIV on T-cell response to COVID-19. News-Medical. Retrieved on April 26, 2024 from https://www.news-medical.net/news/20220410/The-effect-of-unsuppressed-HIV-on-T-cell-response-to-COVID-19.aspx.

  • MLA

    Bose, Priyom. "The effect of unsuppressed HIV on T-cell response to COVID-19". News-Medical. 26 April 2024. <https://www.news-medical.net/news/20220410/The-effect-of-unsuppressed-HIV-on-T-cell-response-to-COVID-19.aspx>.

  • Chicago

    Bose, Priyom. "The effect of unsuppressed HIV on T-cell response to COVID-19". News-Medical. https://www.news-medical.net/news/20220410/The-effect-of-unsuppressed-HIV-on-T-cell-response-to-COVID-19.aspx. (accessed April 26, 2024).

  • Harvard

    Bose, Priyom. 2023. The effect of unsuppressed HIV on T-cell response to COVID-19. News-Medical, viewed 26 April 2024, https://www.news-medical.net/news/20220410/The-effect-of-unsuppressed-HIV-on-T-cell-response-to-COVID-19.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals how SARS-CoV-2 hijacks lung cells to drive COVID-19 severity